Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2

NCT01082926 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01082926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01082926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
September 30, 2013
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ependymoma, anaplastic meningioma, anaplastic oligodendroglioma, brain stem glioma, brain tumor, ependymoblastoma, giant cell glioblastoma, glioblastoma, gliosarcoma, grade iii meningioma, meningeal hemangiopericytoma, mixed glioma, pineal gland astrocytoma